Over 20 Total Lots Up For Auction at One Location - TX Cleansweep 06/25

James Alecxih

ViewRay appoints chief commercial officer
October 16, 2018
MRI Rad Oncology Radiation Therapy
CLEVELAND, Oct. 2, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the appointment of James "Jim" Alecxih as Chief Commercial Officer, effective September 17th, 2018. Mr. Alecxih joins the ViewRay leadership team with extensive experience in commercializing new and innovative devices globally and will be responsible for driving the Company's commercial expansion.

Prior to joining ViewRay, Mr. Alecxih served as Vice President of Worldwide Sales at Nevro, where he led the high-growth neuromodulation device company's commercial efforts across multiple geographies. Mr. Alecxih also spent 14 years at Intuitive Surgical, where he served most recently as Senior Vice President of Sales for North America, South America, Australia and New Zealand. At Intuitive Surgical, Jim was integral in driving sales from $9 million annually to more than $1.8 billion annually and coordinated the overall marketing strategy through four product launches and domestic and international expansion.

Earlier in his career, Mr. Alecxih held a variety of sales management roles at Johnson & Johnson's Ethicon Endo-Surgery. He holds a Bachelor of Arts degree in Business from Le Tourneau University.
DOTmed text ad

New Fully Configured 80-slice CT in 2 weeks with Software Upgrades for Life

For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.

"We are excited to welcome Jim as our Chief Commercial Officer as we drive the commercial adoption of the MRIdian system," said Scott Drake, President and Chief Executive Officer of ViewRay. "We are committed to extending our leadership position in the market. Jim's proven track record and relevant experience complement our strategic plans and help drive our ambitious growth goals."

As an inducement material to Mr. Alecxih's entering into employment with ViewRay, ViewRay has agreed to grant Mr. Alecxih a total of 275,000 stock options, effective October 15, 2018. This award will be granted in accordance with Nasdaq Listing Rule 5635(c)(4), has been approved by the Compensation Committee of ViewRay's Board of Directors and will be subject to the terms and conditions of ViewRay's 2015 Stock Incentive Plan and Mr. Alecxih's award agreement. These terms will include a service-based vesting requirement, with the stock options vesting over four years. The options will have an exercise price equal to the closing trading price of ViewRay's common stock on the effective date.

About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology helping to transform radiation therapy, resulting in improved treatment outcomes that benefit both patients and health care systems around the world. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purposely built to deliver high-precision radiation without unnecessary beam distortion, and consequently, help to mitigate skin toxicity and other safety concerns that may otherwise arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

SOURCE ViewRay, Inc.

You Must Be Logged In To Post A Comment


MRI Homepage

Siemens Healthineers unveils dental-only MR prototype at European radiology event
The helium-free MAGNETOM Free.Max Dental Edition was developed in partnership with Dentsply Sirona
New sensor could flag MR scan motion in real time, saving time between repeat exams
Triboelectric nanogenerator-based sensor fits beneath the headrest area
Philips touts 1,111 helium-free MR installations
Company estimates it has saved 1.9 million liters of liquid helium
Improving standard of Prostate Cancer Diagnosis and Care while increasing MRI revenues
Standalone Performance AUROC curve of Bot Image's ProstatID AI Software obtained during clinical studies using retrospective Imaging and Pathology data from various MRI vendors and locations.
First-of-its-kind study will assess MR-guided brain procedures
AiM Medical Robotics and Brigham and Women's Hospital partner on lead placement for DBS
Researchers obtain 3T quality whole-body MR images on a 0.05T scanner
Hong Kong team utilizes deep learning to make helium unnecessary
Ezra direct-to-consumer MR expands New Jersey presence
Partnership with Princeton Radiology adds facilities in the Central and Northern regions of the state
Siemens Healthineers invests $314 million in low-helium MR manufacturing
DryCool cuts MR helium requirement from 1,500 liters to less than one liter
Hyperfine targets European market with portable MR distributor partnerships
Swoop portable MR distributors coming to France, UK and Italy
Siemens and University Hospitals announce 10-year partnership
The aim is to improve the health system’s oncology, cardiovascular, and neurovascular care